Lately, I have been posting videos but there ia limited capability of videos to disseminate graphics or plots. I decided to do a post and video later. The Anavex's data release on the results of Phase 2b/3 included Odds Ratio versus Placebo arm for cognition (MMSE) and Activities of Daily Living (ADCS-ADL). Again, we assume … Continue reading Synthetic Odds Ratios in Phase 2a and Phase 2b/3 in Alzheimer’s Trial for Blarcamesine $AVXL
How The Assuption That All Drugs Should Follow Normal Distribution Has Failed Anavex But Blarcamesien Has Succeeded.
Current Investor's Sentiment Dr Missling, notwithstanding the mishapps with data, has provided two sets of data relevant to investors. The first set consisted of the Means for both Placebo Cohort and the Combined Dosed Cohorts, their respectful Standard Deviations and Standard Errors which then were used to calculate the p-values. The sampling size n was … Continue reading How The Assuption That All Drugs Should Follow Normal Distribution Has Failed Anavex But Blarcamesien Has Succeeded.
Why Placebo Arm Is Critical To Proper Assesment Of Therapeutic Effect In Trials Of Alzheimer’s Disease. The Case of Phase2b/3 For Blarcamesine (Anavex2-73) And Simufilam Open Label. $AVXL $SAVA
The following post is in reference to paper tilted: link: https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2010.03.018 The purpose of this paper is to establish realtionship between covariates like baseline severity, age, APOE4 genotype and gender, and the slope of yearly decline in ADAS-Cog cognition measure. The Conclusions Most Relevant To Investors: The mean slope is dependent mostly on baseline severity … Continue reading Why Placebo Arm Is Critical To Proper Assesment Of Therapeutic Effect In Trials Of Alzheimer’s Disease. The Case of Phase2b/3 For Blarcamesine (Anavex2-73) And Simufilam Open Label. $AVXL $SAVA
Looking To Release Of Information On 50mg Cohort Performance In Phase2b/3. $AVXL Blarcamesine
Let's get down to the nitty gritty of Due Diligence The fact that Phase2b/3 included 30mg cohort makes it just greater n Phase2a? If this question can be aswered in affirmitive than one would expect the 30mg follow placebo, or at least expect most of the responders to reside in the 50mg cohort. Notwithstanding the … Continue reading Looking To Release Of Information On 50mg Cohort Performance In Phase2b/3. $AVXL Blarcamesine
Anavex Life Sciences Phase2a For Alzheimer’s Vindicated with 509 Sample Size Phase2b/3. Blarcamesine $AVXL
Late Means Late The presented data has been just released to Anavex and processed to be delivered just in nick of time to Dr. Farlane to be presented at CTAD 2022. Unfortunately, I had not saved the presentation slides as I initially downloaded them and they have been remoed now. If anybody has a copy … Continue reading Anavex Life Sciences Phase2a For Alzheimer’s Vindicated with 509 Sample Size Phase2b/3. Blarcamesine $AVXL
Final Prognostication Before December 1, 2022 CTAD San Francisco Presentation.
Refined Illustration For Possible Performance of Blarcamesine On The Background of Donezepil, Simufilam and Donezepil Placebo, All Imperfect Comparison First thing is to point to a mistaken plus sign of the Avg. Delta ADAS-COG11, which should be -7.21, not 7.21. Green Line represents the performance of Donezepil Placebo from Donezepil Label Fig.2. But this is … Continue reading Final Prognostication Before December 1, 2022 CTAD San Francisco Presentation.
Donezepil, Simufilam And Blarcamesine Performance Compared As Much As It Is Possible. $SAVA $AVXL
It was suggested to me to comparing the hypothetical performance of Blarcamesine in phase 2b/3 to Donezepil. Hat Tip to @Trainguy1. I tried to compare the 3 drugs, including 9 months performnace of Simufilam, to Donezepil as it was formated or presented in Fig. 2 on Donezepil Label coming with the drug, and FDA approved. … Continue reading Donezepil, Simufilam And Blarcamesine Performance Compared As Much As It Is Possible. $SAVA $AVXL
In Search of Therapeutic Effect Patterns In Simufilam, Blarcamesine and Approximation of Placebo. $SAVA $AVXL
Plotting Δ ΜΜSE or Δ ADAS-Cog11 or Just Changes in Cognition for Each Patient I came with an idea to plot in a given trial all the cognition changes from the highest score to the lowest. On a spreadsheet I arranged patients in this order with their corressponding cognition deltas scores. When you see a … Continue reading In Search of Therapeutic Effect Patterns In Simufilam, Blarcamesine and Approximation of Placebo. $SAVA $AVXL
Comparing Apples To Oranges, Or Rather The Hypotetical Performance Of Blarcamesine And Simufilam. $AVXL vs. $SAVA
This is quick and dirty, I have no time for bibliography and references. I had been giving references links but now I have no time so if you want references I can provided them on request. For most of you the references for those illustrations are already known. I apologize for misspellings and gramatical errors. … Continue reading Comparing Apples To Oranges, Or Rather The Hypotetical Performance Of Blarcamesine And Simufilam. $AVXL vs. $SAVA
Change Of Language On ClinicalTrials.Gov Page For Blarcamesine Phase 2b/3 Alzheimer’s Trial. $AVXL
You can devine the future from coffee grinds as well as from the language change... But only if you don't know much about the implications of language in phase 2b/3 for Blarcamesine for Alzheimer's. Mr. Brodkin has published this tweet. Link: https://twitter.com/jesse_brodkin/status/1550477966123171840?s=20&t=MdTQ5Aes7PJyFbCFHRQQAQ One of the points he makes is that Anavex has changed the wording … Continue reading Change Of Language On ClinicalTrials.Gov Page For Blarcamesine Phase 2b/3 Alzheimer’s Trial. $AVXL